The synthesis of CP-195543, an LTB4 antagonist for the treatment of inflammatory diseases.
A review of the process research and development of CP-195543 is presented. This chronological depiction from the original medicinal chemistry synthesis, which yielded a few grams of final product, to a novel route which allowed the compound to be prepared in multi-kilogram quantities, demonstrates some of the challenges which pace environment. This project also exemplifies the necessity of communication and collaboration between discovery and the different departments of process research and development in order to proceed quickly from the discovery of a compound to its evaluation in the clinic.
Caron
S
S
Process Research and Development, Pfizer Central Research, PO Box 8013, Groton, CT 6340-8013, USA. stephane_caron@groton.pfizer.com